“It is time to offer genetic screening of BRCA1 and BRCA2 genes to every women”

Uterine (endometrial or womb) cancer is the 2nd most common cancer type in women. Approximately 3% of women will be diagnosed with endometrial cancer at some point during their lifetime (life time risk).

Around 5-10% uterine cancer cases are hereditary due to inherited mutations in cancer predisposition genes, such as: MMR genes (MLH1, MSH2, MSH6, PMS2, EPCAM), TP53, PTEN, STK11 and others.

Mutations in MMR genes cause Lynch syndrome and increase risk of colorectal, uterine, stomach, ovarian and other cancer types.

Hereditary endometrial (uterine) cancer genes

Comprehensive oncogenetic test of gene panels using modern next generation sequencing (NGS) technology is the most precise method for genetic breast cancer risk assessment.

A single comprehensive genetic ONCORISK61 test evaluate cancer predisposing mutations in 61 genes at once, at least 10 of which are associated with increased uterine cancer risk (mutations in other genes are associated with other cancer risk, such as breast, ovarian, colorectal, stomach, pancreas, skin, prostate): BRCA1, BRCA2, TP53, PTEN, STK11, CDH1, PALB2, ATM, BRIP1, BARD1, CHEK2,  RAD51C, RAD51D, MLH1, MSH2, MSH6, PMS2, EPCAM, AXIN2, NTHL1, MSH3, MUTYH, APC, BMPR1A, SMAD4, GREM1, POLD1, POLE, NBN, MITF, BAP1, CDKN2A, CDK4.